Off-label uses of Sorafenib and Sunitinib

BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

The BlueCross BlueShield Association Technology Evaluation Center website (www.bcbs.com/tec) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website.

Citation

Authors' objectives
The Assessment summarizes and evaluates evidence on health outcomes of sorafenib and sunitinib for off-label indications reported in published studies or currently undergoing phase III trials. Since these medications overlap only partially with respect to the receptor tyrosine kinases each inhibits, sorafenib and sunitinib were assessed separately.

Project page URL
http://www.bcbs.com/blueresources/tec/contact-tec.html

Indexing Status
Subject indexing assigned by NLM

MeSH
Adenocarcinoma /drug therapy; Angiogenesis Inhibitors /therapeutic use; Breast Neoplasms /drug therapy; Carcinoma, Non-Small-Cell Lung /drug therapy; Clinical Trials, Phase III as Topic; Digestive System Neoplasms /drug therapy; Drug Approval; Female; Gastrointestinal Stromal Tumors /drug therapy; Head and Neck Neoplasms /drug therapy; Indoles /pharmacology; Male; Melanoma /drug therapy; Neoplasms, Squamous Cell /drug therapy; Product Labeling; Pyridines /pharmacology; Pyrroles /pharmacology; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration

Language Published
English

Country of organisation
United States

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32010000210

Date abstract record published
24/03/2010